AbbVie Inc.

Equities

Market Closed - Nyse Other stock markets 21:01:41 17/04/2026 BST			5-day change	1st Jan Change
208.38 ^USD	-0.29%		+0.21%	-8.80%

04-16	Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026	CI
04-15	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT

Published on 03/10/2026 at 04:35 pm GMT - Modified on 03/10/2026 at 06:05 pm GMT

S&P Capital IQ

Presenter Speech
David Risinger (Analysts)

So good morning, everyone. My name is Dave Risinger. I'm very pleased to host a couple of senior executives from AbbVie.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

04-16	Helus Pharma Appoints Dr. Ken Kramer as Senior Vice President, Medical Affairs, Effective April 16, 2026	CI
04-15	Johnson & Johnson Reported Above-Peer Topline Growth in Q1, BofA Says	MT
04-15	RemeGen Receives $650 Million Upfront Payment From AbbVie Under Licensing Agreement	MT
04-13	Evercore ISI Adjusts AbbVie Price Target to $232 From $233, Maintains Outperform Rating	MT
04-13	Earnings Season in Trump's Shadow
04-13	CollPlant Biotechnologies Ltd and Allergan Industrie SAS Terminate Development Agreement	CI
04-13	Haisco Pharmaceutical Group Co., Ltd. Enters Exclusive License Agreement with AbbVie	CI
04-13	Chinese Stocks Muted Amid Failed US-Iran Talks, Improved GDP Outlook	MT
04-13	AbbVie Signs Global Pain Drug Licensing Deal With Haisco	MT
04-12	Abbvie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-Gynx in Platinum-Sensitive Ovarian Cancer	CI
04-12	AbbVie Showcases Late-Breaking Phase 2 Data for Mirvetuximab Soravtansine-gynx in Platinum-Sensitive Ovarian Cancer	CI
04-12	Haisco Pharmaceutical signs licensing agreement with AbbVie Group	RE
04-10	AbbVie First-Quarter Earnings Unlikely to Lift Sentiment, RBC Says	MT
04-10	Guggenheim Adjusts Price Target on AbbVie to $249 From $242, Maintains Buy Rating	MT
04-09	Biopharma Stocks Largely Exempt From Pharma Tariffs, BofA Says	MT